Literature DB >> 21338243

Efficacy and safety of propranolol in the treatment of parotid hemangioma.

Paulo Morais1, Sofia Magina, Mário Mateus, Eunice Trindade, José Miguel Jesus, Filomena Azevedo.   

Abstract

A 2-month-old female patient presented an extensive bilateral parotid hemangioma (PH) focally ulcerated. Additionally, hepatic ultrasonography revealed a hemangioendothelioma located at right lobe. She was treated with oral prednisolone (3 mg/kg/day) during 10 months with clinical improvement of PH, despite failure to thrive and arterial hypertension. However, regrowth of the lesion occurred after discontinuation of oral steroid. Propranolol hydrochloride (2 mg/kg/day divided into two doses) was then started and maintained for 16 months, with marked involution of the hemangioma and with no systemic side effects during treatment course. Curiously, also the liver hemangioendothelioma completely resolved after starting propranolol. PH is a threatening cervicofacial segmental hemangioma that frequently proliferates after the year of age and needs long-term treatment. On the other hand, hepatic hemangioendotheliomas may be associated with cutaneous hemangiomas in some patients and their natural history is similar to these, although patients may die of associated conditions. As for other infantile hemangiomas, propranolol proved to be an effective, safe, and well-tolerated treatment for PH. Its role in liver hemangiomas and hemangioendotheliomas should also be taken into account.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338243     DOI: 10.3109/15569527.2011.554483

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  3 in total

1.  Trismus Resulting from Infantile Hemangioma of the Parotid: A Rare Case Report.

Authors:  E Zarepur; M Moghimi
Journal:  Iran J Ped Hematol Oncol       Date:  2015-12-10

Review 2.  Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.

Authors:  Fahad Aljebab; Imti Choonara; Sharon Conroy
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

3.  Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

Authors:  Jessica M Stiles; Clarissa Amaya; Steven Rains; Dolores Diaz; Robert Pham; James Battiste; Jaime F Modiano; Victor Kokta; Laura E Boucheron; Dianne C Mitchell; Brad A Bryan
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.